Dr. Fred Grossman, DO, FAPA is President and Chief Medical Officer of Glenmark Pharmaceuticals Ltd. He oversees global clinical development, pharmacovigilance, medical affairs and clinical operations for innovative product development, as well as specialty and generic products. In this role, he furthers Glenmark’s investments in research to generate assets that address unmet medical needs in a variety of therapeutic areas. Dr. Grossman has more than 20 years of international experience directing research and development for potential new medicines for leading pharmaceutical organizations. Before joining Glenmark in 2015, he held global medical leadership positions at Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, and Sunovion. Dr. Fred Grossman, DO, FAPA is President and Chief Medical Officer of Glenmark Pharmaceuticals Ltd. He oversees global clinical development, pharmacovigilance, medical affairs and clinical operations for innovative product development, as well as specialty and generic products. In this role, he furthers Glenmark’s investments in research to generate assets that address unmet medical needs in a variety of therapeutic areas. Dr. Grossman has more than 20 years of international experience directing research and development for potential new medicines for leading pharmaceutical organizations. Before joining Glenmark in 2015, he held global medical leadership positions at Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, and Sunovion.

Intrested in clinical and researh development.